Do analysts prefer ENVB or CYCN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ENVB or SCNX?

Scienture has a consensus target price of $1.50, suggesting a potential upside of 263.02%. Given Scienture's stronger consensus rating and higher probable upside, analysts clearly believe Scienture is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ENVB or SCNX more profitable?

Scienture's return on equity of -53.51% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Enveric Biosciences N/A -168.04% -145.95% Scienture N/A -53.51% -42.47%

Do analysts recommend VYNE or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ENVB or LEXX?

Lexaria Bioscience has a consensus target price of $22.50, indicating a potential upside of 93.97%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Enveric Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ENVB or LEXX more profitable?

Enveric Biosciences' return on equity of -168.04% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Enveric Biosciences N/A -168.04% -145.95% Lexaria Bioscience N/A -174.93% -143.89%

Do analysts recommend BFRI or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to BFRI or ENVB?

In the previous week, Biofrontera had 1 more articles in the media than Enveric Biosciences. MarketBeat recorded 3 mentions for Biofrontera and 2 mentions for Enveric Biosciences. Biofrontera's average media sentiment score of 0.00 equaled Enveric Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enveric Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Enveric Biosciences (ENVB) Competitors

$1.46 +0.05 (+3.55%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$1.46 0.00 (-0.34%)

As of 08/25/2026 05:42 PM Eastern

Compare

ENVB vs. CYCN, SCNX, VYNE, LEXX, and BFRI

Should you buy Enveric Biosciences stock or one of its competitors? Enveric Biosciences's main competitors and comparable companies include Cyclerion Therapeutics (CYCN), Scienture (SCNX), VYNE Therapeutics (VYNE), Lexaria Bioscience (LEXX), and Biofrontera (BFRI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Enveric Biosciences compare to Cyclerion Therapeutics?

Enveric Biosciences (NASDAQ:ENVB) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 2.4% of Enveric Biosciences shares are held by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Enveric Biosciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

In the previous week, Enveric Biosciences had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Enveric Biosciences and 1 mentions for Cyclerion Therapeutics. Enveric Biosciences' average media sentiment score of 0.00 equaled Cyclerion Therapeutics'average media sentiment score.

Company	Overall Sentiment
Enveric Biosciences	Neutral
Cyclerion Therapeutics	Neutral

Cyclerion Therapeutics has higher revenue and earnings than Enveric Biosciences. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A
Cyclerion Therapeutics	$2.07M	9.04	-$3.53M	-$1.66	N/A

Enveric Biosciences has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -87.96% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-168.04%	-145.95%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

Summary

Cyclerion Therapeutics beats Enveric Biosciences on 8 of the 11 factors compared between the two stocks.

How does Enveric Biosciences compare to Scienture?

Enveric Biosciences (NASDAQ:ENVB) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

Scienture has a consensus target price of $1.50, suggesting a potential upside of 263.02%. Given Scienture's stronger consensus rating and higher probable upside, analysts clearly believe Scienture is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enveric Biosciences has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Scienture has a beta of 3.26, indicating that its share price is 226% more volatile than the broader market.

Enveric Biosciences has higher earnings, but lower revenue than Scienture. Scienture is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A
Scienture	$430K	39.46	-$41.51M	-$2.10	N/A

13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 2.4% of Enveric Biosciences shares are held by company insiders. Comparatively, 21.4% of Scienture shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Enveric Biosciences had 1 more articles in the media than Scienture. MarketBeat recorded 2 mentions for Enveric Biosciences and 1 mentions for Scienture. Enveric Biosciences' average media sentiment score of 0.00 equaled Scienture'saverage media sentiment score.

Company	Overall Sentiment
Enveric Biosciences	Neutral
Scienture	Neutral

Scienture's return on equity of -53.51% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-168.04%	-145.95%
Scienture	N/A	-53.51%	-42.47%

Summary

Scienture beats Enveric Biosciences on 9 of the 13 factors compared between the two stocks.

How does Enveric Biosciences compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Enveric Biosciences has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Enveric Biosciences	N/A	-168.04%	-145.95%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

83.8% of VYNE Therapeutics shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 3.0% of VYNE Therapeutics shares are owned by insiders. Comparatively, 2.4% of Enveric Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

VYNE Therapeutics has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Enveric Biosciences has lower revenue, but higher earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	33.29	-$26.48M	-$0.38	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A

In the previous week, Enveric Biosciences had 2 more articles in the media than VYNE Therapeutics. MarketBeat recorded 2 mentions for Enveric Biosciences and 0 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 0.00 equaled Enveric Biosciences'average media sentiment score.

Company	Overall Sentiment
VYNE Therapeutics	Neutral
Enveric Biosciences	Neutral

Summary

VYNE Therapeutics beats Enveric Biosciences on 7 of the 11 factors compared between the two stocks.

How does Enveric Biosciences compare to Lexaria Bioscience?

Enveric Biosciences (NASDAQ:ENVB) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Enveric Biosciences and Enveric Biosciences both had 2 articles in the media. Enveric Biosciences' average media sentiment score of 0.00 equaled Lexaria Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Enveric Biosciences	Neutral
Lexaria Bioscience	Neutral

Enveric Biosciences has higher earnings, but lower revenue than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A
Lexaria Bioscience	$710K	26.96	-$11.90M	-$5.10	N/A

Enveric Biosciences' return on equity of -168.04% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-168.04%	-145.95%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Enveric Biosciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 2.4% of Enveric Biosciences shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lexaria Bioscience has a consensus target price of $22.50, indicating a potential upside of 93.97%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Enveric Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lexaria Bioscience beats Enveric Biosciences on 7 of the 12 factors compared between the two stocks.

How does Enveric Biosciences compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Enveric Biosciences has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Enveric Biosciences	N/A	-168.04%	-145.95%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Enveric Biosciences has lower revenue, but higher earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.54	-$10.54M	-$0.45	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$12.65	N/A

Biofrontera has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

In the previous week, Biofrontera had 1 more articles in the media than Enveric Biosciences. MarketBeat recorded 3 mentions for Biofrontera and 2 mentions for Enveric Biosciences. Biofrontera's average media sentiment score of 0.00 equaled Enveric Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enveric Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 8.1% of Biofrontera shares are owned by insiders. Comparatively, 2.4% of Enveric Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Biofrontera beats Enveric Biosciences on 8 of the 13 factors compared between the two stocks.

Get Enveric Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENVB vs. The Competition

Export

Metric	Enveric Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.31M	$12.54B	$7.35B	$12.72B
Dividend Yield	N/A	2.61%	2.53%	11.02%
P/E Ratio	-0.12	778.14	270.96	24.14
Price / Sales	N/A	754.40	634.76	101.59
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	0.81	12.02	13.14	6.25
Net Income	-$8.77M	$2.80B	$3.46B	$347.86M
7 Day Performance	11.45%	2.88%	1.52%	0.98%
1 Month Performance	13.18%	6.55%	8.82%	5.24%
1 Year Performance	-90.85%	8.09%	26.08%	17.04%

Enveric Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENVB Enveric Biosciences	0.7661 of 5 stars	$1.46 +3.5%	N/A	-90.8%	$6.31M	N/A	N/A	20	Analyst Upgrade Gap Up
CYCN Cyclerion Therapeutics	0.6125 of 5 stars	$4.15 +0.6%	N/A	+56.9%	$19.41M	$2.07M	N/A	30
SCNX Scienture	1.9293 of 5 stars	$0.47 +3.3%	$1.50 +217.8%	-60.6%	$19.18M	$430K	N/A	N/A
VYNE VYNE Therapeutics	0.2947 of 5 stars	$28.33 -0.8%	N/A	+74.2%	$18.98M	$570K	N/A	30	Gap Down High Trading Volume
LEXX Lexaria Bioscience	2.0187 of 5 stars	$11.44 -0.7%	$22.50 +96.8%	-26.3%	$18.93M	$710K	N/A	7	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENVB) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enveric Biosciences (ENVB) Competitors

ENVB vs. CYCN, SCNX, VYNE, LEXX, and BFRI

How does Enveric Biosciences compare to Cyclerion Therapeutics?

Summary

How does Enveric Biosciences compare to Scienture?

Summary

How does Enveric Biosciences compare to VYNE Therapeutics?

Summary

How does Enveric Biosciences compare to Lexaria Bioscience?

Summary

How does Enveric Biosciences compare to Biofrontera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB vs. The Competition

Enveric Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enveric Biosciences (ENVB) Competitors

ENVB vs. CYCN, SCNX, VYNE, LEXX, and BFRI

How does Enveric Biosciences compare to Cyclerion Therapeutics?

Do institutionals & insiders hold more shares of ENVB or CYCN?

Do analysts prefer ENVB or CYCN?

Which has more risk & volatility, ENVB or CYCN?

Does the media refer more to ENVB or CYCN?

Which has higher earnings & valuation, ENVB or CYCN?

Is ENVB or CYCN more profitable?

Summary

How does Enveric Biosciences compare to Scienture?

Do analysts recommend ENVB or SCNX?

Which has more risk & volatility, ENVB or SCNX?

Which has better earnings and valuation, ENVB or SCNX?

Do institutionals and insiders have more ownership in ENVB or SCNX?

Does the media prefer ENVB or SCNX?

Is ENVB or SCNX more profitable?

Summary

How does Enveric Biosciences compare to VYNE Therapeutics?

Is VYNE or ENVB more profitable?

Do analysts recommend VYNE or ENVB?

Do institutionals and insiders believe in VYNE or ENVB?

Which has more volatility and risk, VYNE or ENVB?

Which has preferable valuation and earnings, VYNE or ENVB?

Does the media prefer VYNE or ENVB?

Summary

How does Enveric Biosciences compare to Lexaria Bioscience?

Does the media refer more to ENVB or LEXX?

Which has higher valuation and earnings, ENVB or LEXX?

Is ENVB or LEXX more profitable?

Which has more risk & volatility, ENVB or LEXX?

Do institutionals and insiders have more ownership in ENVB or LEXX?

Do analysts rate ENVB or LEXX?

Summary

How does Enveric Biosciences compare to Biofrontera?

Is BFRI or ENVB more profitable?

Do analysts recommend BFRI or ENVB?

Which has stronger valuation and earnings, BFRI or ENVB?

Which has more risk and volatility, BFRI or ENVB?

Does the media refer more to BFRI or ENVB?

Do institutionals & insiders hold more shares of BFRI or ENVB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENVB vs. The Competition

Enveric Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools